title: [Treatment effects of antithrombin-III on coagulation abnormalities in rats with endotoxaemia].
abstract: OBJECTIVE
  To study the treatment effects of antithrombin-III (AT-III) on coagulation abnormalities in rats with endotoxaemia.
  
  
  METHODS
  Twenty-four Wistar rats were randomly divided into control group, coagulation abnormality group and AT-III group (each n=8). Endotoxaemia coagulopathy model was reproduced by intravenous injection of lipopolysaccharide (LPS) in two doses of 1.4 ml/kg (100 microg) and 2.8 ml/kg (200 microg) 12 hours apart. In the AT-III group, AT-III 25 U/kg was given intravenously 1 hour after second injection of LPS. The changes in blood platelet (PLT) count, activated partial thromboplastin time (APTT), prothrombin time (PT), D-dimer (DD), AT-III activity, fibrinogen (FI), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) were determined 3 hours later.
  
  
  RESULTS
  Levels of PLT, FI and AT-III in coagulation abnormality group were lowered compared with control group (all P<0.01), while APTT, DD, PT, ALT, AST, ALP and LDH were increased (all P<0.01). All indexes were significantly improved in AT-III group, the values were close to those of normal control group (all P>0.05), and the differences were significant when compared with those of coagulation abnormality group (all P<0.01). Pathological changes of the lung, kidney and liver tissues were lighter in AT-III group than those of coagulation abnormality group.
  
  
  CONCLUSIONS
  These findings indicate that AT-III can be used to treat disseminated intravascular coagulation (DIC) in rats with endotoxaemia. Preventive use of AT-III in rats with endotoxaemia is therapeutically effective.
authors: Tianjin Tianhe Hospital, Tianjin 300050, China.
authors: You-jie
authors: YJ
authors: Qiao
authors: Jun-mei
authors: JM
authors: Zhu
authors: Xi-lei
authors: XL
authors: You
authors: Yu
authors: Y
authors: Zhang
mesh_terms: D000818:Animals; D000925:Anticoagulants / Q000627:therapeutic use*; D000990:Antithrombin III / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004211:Disseminated Intravascular Coagulation / Q000188:drug therapy* / Q000209:etiology; D019446:Endotoxemia / Q000150:complications*; D005260:Female; D008297:Male; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar
chemical_list: D000925:Anticoagulants; D000990:Antithrombin III